Literature DB >> 6745731

Stage III epithelial ovarian cancer: the role of maximal surgical reduction.

G Delgado, D H Oram, E S Petrilli.   

Abstract

One hundred forty-two cases of ovarian cancer of epithelial origin treated at Georgetown University Hospital between 1974 and 1980 were analyzed. Seventy-five patients (52.8%) were found to have Stage III disease at the time of the initial laparotomy, and the purpose of this study was to assess the outcome of the management in this group of patients. In spite of an aggressive approach, complete tumor excision could only be affected in 13 of the 75 Stage III cases (17.3%). Residual disease of less than 2 cm was achieved in a further 8 cases (10.7%). The ability to perform complete tumor clearance bore no relationship to the grade of the tumor. The survival rate in the complete clearance group was 100% with a mean survival time of 45 months (range 10-90 months) and 10 of these patients have been shown to be free of disease by second-look laparotomy. The outcome in terms of survival and disease-free status in these two groups of patients was unaffected by various chemotherapy regimens and the only factor of importance appeared to be the success of the initial surgery in clearing the disease.

Entities:  

Mesh:

Year:  1984        PMID: 6745731     DOI: 10.1016/0090-8258(84)90040-4

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

1.  [Surgical therapy of ovarian cancer].

Authors:  A Pfleiderer
Journal:  Arch Gynecol Obstet       Date:  1987       Impact factor: 2.344

2.  Surgical debulking of ovarian cancer: what difference does it make?

Authors:  John O Schorge; Christopher McCann; Marcela G Del Carmen
Journal:  Rev Obstet Gynecol       Date:  2010

3.  The role of liver-directed surgery in patients with hepatic metastasis from a gynecologic primary carcinoma.

Authors:  Sarah I Kamel; Mechteld C de Jong; Richard D Schulick; Teresa P Diaz-Montes; Christopher L Wolfgang; Kenzo Hirose; Barish H Edil; Michael A Choti; Robert A Anders; Timothy M Pawlik
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

4.  Hepatic resection for metachronous metastases from ovarian carcinoma.

Authors:  Jesus Gonzalez Bosquet; Melissa A Merideth; Karl C Podratz; David M Nagorney
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

5.  Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach.

Authors:  C J Langer; N Rosenblum; M Hogan; S Nash; P Bagchi; F P LaCreta; R Catalano; R L Comis; P J O'Dwyer
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 6.  Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer.

Authors:  Khadra Galaal; Raj Naik; Robert E Bristow; Amit Patel; Andrew Bryant; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

7.  Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection.

Authors:  T Onda; H Yoshikawa; T Yasugi; M Yamada; K Matsumoto; Y Taketani
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

Review 8.  Surgical cytoreduction for recurrent epithelial ovarian cancer.

Authors:  Thuria Al Rawahi; Alberto D Lopes; Robert E Bristow; Andrew Bryant; Ahmed Elattar; Supratik Chattopadhyay; Khadra Galaal
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

9.  Infection versus cancer: management of actinomyces mimicking cervical cancer or ovarian cancer.

Authors:  Diego Odetto; Myriam Perrotta; Jose Martin Saadi; Carolina Beatriz Chacon; Pamela Ines Causa Andrieu; Alejandra Wernicke; Marie Catherine Saez Perrotta
Journal:  Int J Gynecol Cancer       Date:  2020-08-04       Impact factor: 4.661

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.